Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT07148414

A Study of SPY072 in Rheumatic Disease

Led by Spyre Therapeutics, Inc. · Updated on 2026-05-08

285

Participants Needed

64

Research Sites

136 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease (RD).

CONDITIONS

Official Title

A Study of SPY072 in Rheumatic Disease

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 years and older
  • For rheumatoid arthritis: moderate-to-severely active RA with 4 or more swollen joints and 4 or more tender joints at screening and Day 1
  • Positive rheumatoid factor or anti-citrullinated peptide antibodies at screening, or radiology showing erosions consistent with RA
  • Inadequate response to at least 1 conventional synthetic disease-modifying anti-rheumatic drug and/or up to 2 classes of biologic or targeted synthetic DMARDs
  • For axial spondyloarthritis: moderate-to-severely active axSpA with BASDAI score of 4 or higher and back pain score of 4 or higher at screening and Day 1
  • High-sensitivity C-reactive protein above normal at screening
  • Inadequate response to 2 different NSAIDs at maximum tolerated dose for 4 weeks or intolerance to NSAIDs, and/or up to 2 classes of biologic or targeted synthetic DMARDs for at least 12 weeks
  • For psoriatic arthritis: tender joint count of 3 or more and swollen joint count of 3 or more at screening and Day 1
  • At least 1 active plaque psoriasis lesion or a history of psoriasis
  • Inadequate response to at least 1 NSAID, at least 1 conventional synthetic DMARD, and/or up to 2 classes of biologic or targeted synthetic DMARDs
Not Eligible

You will not qualify if you...

  • Inadequate response to more than 2 classes of biologic or targeted synthetic DMARDs
  • Presence of other autoimmune, rheumatologic, inflammatory diseases or pain-amplification syndromes that could affect the evaluation of SPY072 efficacy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 64 locations

1

Site 113

Avondale, Arizona, United States, 85392

Actively Recruiting

2

Site 118

Tucson, Arizona, United States, 85748

Actively Recruiting

3

Site 114

Chula Vista, California, United States, 91910

Actively Recruiting

4

Site 111

Covina, California, United States, 91722

Actively Recruiting

5

Site 108

Tujunga, California, United States, 91042

Actively Recruiting

6

Site 112

Upland, California, United States, 91786

Actively Recruiting

7

Site 107

Whittier, California, United States, 90602

Actively Recruiting

8

Site 115

Aventura, Florida, United States, 33180

Actively Recruiting

9

Site 109

Hialeah, Florida, United States, 33016

Actively Recruiting

10

Site 106

Ormond Beach, Florida, United States, 32174

Actively Recruiting

11

Site 110

Tampa, Florida, United States, 33614

Actively Recruiting

12

Site 116

Willowbrook, Illinois, United States, 60527

Actively Recruiting

13

Site 119

Rockville, Maryland, United States, 20850

Actively Recruiting

14

Site 104

Duncansville, Pennsylvania, United States, 16635

Actively Recruiting

15

Site 105

Corpus Christi, Texas, United States, 78404

Actively Recruiting

16

Site 120

Irving, Texas, United States, 75039

Actively Recruiting

17

Site 103

Tomball, Texas, United States, 77375

Actively Recruiting

18

Site 102

Tomball, Texas, United States, 77377

Actively Recruiting

19

Site 503

Lovech, Lovech, Bulgaria, 5500

Actively Recruiting

20

Site 502

Pleven, Pleven, Bulgaria, 5803

Actively Recruiting

21

Site 506

Plovdiv, Plovdiv, Bulgaria, 4000

Actively Recruiting

22

Site 505

Plovdiv, Plovdiv, Bulgaria, 4003

Actively Recruiting

23

Site 504

Varna, Varna, Bulgaria, 9000

Actively Recruiting

24

Site 706

Hlučín, Hlučín, Czechia, 748 01

Actively Recruiting

25

Site 702

Moravská Ostrava, Ostrava-město, Czechia, 702 00

Actively Recruiting

26

Site 704

Pardubice, Pardubice Region, Czechia, 530 02

Actively Recruiting

27

Site 705

Prague, Praha, Hlavní Mesto, Czechia, 130 00

Actively Recruiting

28

Site 703

Prague, Praha, Hlavní Mesto, Czechia, 140 00

Actively Recruiting

29

Site 701

Uherské Hradiště, Zlín, Czechia, 68601

Actively Recruiting

30

Site 303

Tbilisi, K'alak'i T'bilisi, Georgia, 0102

Actively Recruiting

31

Site 304

Tbilisi, K'alak'i T'bilisi, Georgia, 0112

Actively Recruiting

32

Site 301

Tbilisi, K'alak'i T'bilisi, Georgia, 0159

Actively Recruiting

33

Site 307

Tbilisi, K'alak'i T'bilisi, Georgia, 0172

Actively Recruiting

34

Site 305

Tbilisi, K'alak'i T'bilisi, Georgia, 0186

Actively Recruiting

35

Site 308

Batumi, Georgia, 6010

Actively Recruiting

36

Site 302

Kutaisi, Georgia, 4600

Actively Recruiting

37

Site 306

Tbilisi, Georgia, 0186

Actively Recruiting

38

Site 201

Chisinau, Moldova, MD-2025

Actively Recruiting

39

Site 202

Chisinau, Moldova, MD-2025

Actively Recruiting

40

Site 401

Krakow, Lesser Poland Voivodeship, Poland, 30-363

Actively Recruiting

41

Site 407

Nowa Sól, Lubusz Voivodeship, Poland, 67-100

Actively Recruiting

42

Site 404

Lodz, Lódzkie, Poland, 91-363

Actively Recruiting

43

Site 403

Warsaw, Masovian Voivodeship, Poland, 02-677

Actively Recruiting

44

Site 402

Opole, Opole Voivodeship, Poland, 45-819

Actively Recruiting

45

Site 406

Gdynia, Pomeranian Voivodeship, Poland, 81-384

Actively Recruiting

46

Site 405

Warszawa, Pomeranian Voivodeship, Poland, 00-874

Actively Recruiting

47

Site 408

Elblag, Warmian-Masurian Voivodeship, Poland, 82-300

Actively Recruiting

48

Site 602

A Coruña, A Coruña, Spain, 15006

Actively Recruiting

49

Site 604

Chiclana de la Frontera, Cadiz, Spain, 11139

Actively Recruiting

50

Site 601

Santander, Madrid, Spain, 39008

Actively Recruiting

51

Site 603

Seville, Sevilla, Spain, 41010

Actively Recruiting

52

Site 809

Chernihiv, Chernihiv Oblast, Ukraine, 14029

Actively Recruiting

53

Site 813

Kyiv, Kyiv Oblast, Ukraine, 02091

Actively Recruiting

54

Site 806

Kyiv, Kyiv Oblast, Ukraine, 03049

Actively Recruiting

55

Site 804

Kyiv, Kyiv Oblast, Ukraine, 04050

Actively Recruiting

56

Site 803

Kyiv, Kyiv Oblast, Ukraine, 2125

Actively Recruiting

57

Site 805

Kyiv, Kyiv Oblast, Ukraine, 4106

Actively Recruiting

58

Site 807

Lviv, Lviv Oblast, Ukraine, 79044

Actively Recruiting

59

Site 808

Ternopil, Ternopil Oblast, Ukraine, 46002

Actively Recruiting

60

Site 810

Ternopil, Ternopil Oblast, Ukraine, 46002

Actively Recruiting

61

Site 801

Vinnytsia, Vinnytsia Oblast, Ukraine, 21028

Actively Recruiting

62

Site 802

Vinnytsia, Vinnytsia Oblast, Ukraine, 21029

Actively Recruiting

63

Site 812

Vinnytsia, Vinnytska, Ukraine, 21000

Actively Recruiting

64

Site 811

Zhytomyr, Zhytomyr Oblast, Ukraine, 10002

Actively Recruiting

Loading map...

Research Team

S

SKYWAY-RD Trial Center

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

7

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here